Palvella Therapeutics, Inc. (PVLA) Cash Flow Statement
Palvella Therapeutics, Inc. (PVLA) generated -$36.5M of operating cash flow over the twelve months to 2026-06-30, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PVLAPalvella Therapeutics, Inc.Follow PVLA — free
—
Price chart with a free account
- Market cap
- 1.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 17 Nov, in 24 days
| Line | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -5.1 | -12.7 | -14.4 | 49.8 | -1.1 | -52.5 | -45.9 | -7.7 | -59.9 | -13.7 | -10.8 | -25.0 | -36.5 | |
| Capital expenditure | 0.3 | 0.6 | 0.6 | 2.0 | 1.7 | 2.5 | 2.7 | 0.9 | 1.0 | 0.2 | — | — | — | |
| Free cash flow | -5.3 | -13.3 | -14.9 | 47.8 | -2.8 | -54.9 | -48.6 | -8.6 | -61.0 | -13.9 | — | — | — | |
| Stock-based compensation | 0.6 | 1.2 | 1.9 | 3.0 | 4.9 | 5.4 | 5.1 | 5.2 | 4.4 | 0.6 | 0.8 | 6.4 | — |
USD millions · SEC XBRL
Palvella Therapeutics, Inc. — questions
- What is Palvella Therapeutics, Inc.'s operating cash flow?
- -$36.5M over the twelve months to 2026-06-30.
Every figure on this page comes from Palvella Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.